Actively Recruiting
Evaluating Efgartigimod PH20 SC Treatment in Children Aged 2 to Under 18 With Generalized Myasthenia Gravis An Open-Label Safety and Activity Study
Led by argenx · Updated on 2026-09-28
12
Participants Needed
22
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to study the pharmacokinetics, pharmacodynamics, safety, tolerability, and immune response of efgartigimod PH20 SC in children aged 2 to less than 18 years with generalized Myasthenia Gravis gMG. The main goal is to find the right dose of this treatment for pediatric patients based on how the drug behaves in their bodies and its effects. Participants will be monitored closely throughout the study to ensure safety and gather important data. Participants will receive subcutaneous injections of efgartigimod PH20 SC during the treatment period. The study is open-label and uncontrolled, meaning all participants receive the active treatment without comparison to a placebo. The treatment and monitoring will last up to 14 weeks, after which eligible participants may join an open-label extension study for further evaluation. During the study, participants will undergo various assessments including blood tests to measure drug levels, immunoglobulin G IgG, and anti-acetylcholine receptor antibodies. Researchers will track adverse events, antibody development against the drug, and clinical scores relevant to Myasthenia Gravis symptoms and quality of life. Safety monitoring continues until the study ends, ensuring careful observation of participants throughout their involvement.
CONDITIONS
Brief Title
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Research Team
S
Sabine Coppieters, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here